BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
GILD upcoming catalysts
Gilead Sciences: 3 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 13 readout(s) and 5 FDA event(s). Subscribe to GILD (.ics).
Drugs: Sacituzumab Govitecan-hziy, Lenacapavir, Gemcitabine, Emtricitabine/tenofovir disoproxil fumarate, Eribulin Mesylate, Capecitabine Product, Vinorelbine, Tilpisertib Fosmecarbil, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Carboplatin
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Gilead Sciences GILD | NCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | Metastatic Breast Cancer | active not recruiting | 331 |
| 2027-01 est. | P2 | Gilead Sciences GILD | NCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 176 |
| 2027-02 est. | P3 | Gilead Sciences GILD | NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Ad | Triple Negative Breast Cancer; PD-L1 Positive | active not recruiting | 443 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-08-27 | FDA approval | approved | GILEAD SCIENCES INC GILD | BIXLENVO | Approved 2026-08-27: BIXLENVO (NDA221104 ORIG1) |
| 2026-08-27 | FDA approval | approved | GILEAD SCIENCES INC GILD | BIXLENVO SUNLENCA STARTER PACK | Approved 2026-08-27: BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) (NDA221443 ORIG1) |
| 2026-08-27 | FDA approval | approved | GILEAD SCIENCES INC GILD | SUNLENCA | Approved 2026-08-27: SUNLENCA (NDA215973 SUPPL24) |
| 2026-08-27 | FDA approval | approved | GILEAD SCIENCES INC GILD | SUNLENCA | Approved 2026-08-27: SUNLENCA (NDA215974 SUPPL17) |
| 2026-05-22 | FDA approval | approved | GILEAD SCIENCES INC GILD | HEPCLUDEX | Approved 2026-05-22: HEPCLUDEX (BLA761468 ORIG1) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-03 | P2/P3 | Gilead Sciences GILD | NCT06544733 Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Su | HIV-1-Infection | terminated | 80 |
| 2026-10-27 | P2 | Gilead Sciences GILD | NCT02932150 Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | active not recruiting | 150 |
| 2026-10 est. | P2 | Gilead Sciences GILD | NCT05119907 Study of Sacituzumab Govitecan in Patients With Solid Tumor | Solid Tumor | active not recruiting | 53 |
| 2026-07-27 | P2 | Gilead Sciences GILD | NCT06101342 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 181 |
| 2026-07-22 | P2 | Gilead Sciences GILD | NCT06101329 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 253 |
| 2026-05-28 | P2 | Gilead Sciences GILD | NCT06513312 Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 268 |
| 2026-05-06 | P3 | Gilead Sciences GILD | NCT06060665 Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) | Primary Biliary Cholangitis | completed | 96 |
| 2026-04-23 | P3 | Gilead Sciences GILD | NCT06630299 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 | HIV-1-Infection | active not recruiting | 600 |
| 2026-04-17 | P3 | Gilead Sciences GILD | NCT06630286 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV- | HIV-1-infection | active not recruiting | 609 |
| 2026-03-16 | P2/P3 | Gilead Sciences GILD | NCT06613685 Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated | HIV-1-infection | terminated | 73 |
| 2026-03-04 | P2 | Gilead Sciences GILD | NCT06290934 Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 228 |
| 2025-12-17 | P2 | Gilead Sciences GILD | NCT05629208 Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Cutaneous Lupus Erythematosus (CLE) | terminated | 20 |
| 2025-12 est. | P2 | Gilead Sciences GILD | NCT06682234 Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease | Filovirus Disease; Postexposure Prophylaxis for Filovirus Disease | withdrawn |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.